Risk of liver fibrosis in patients undergoing surgical treatment of hip trauma

Česká verzia

Authors: M. Sedlář ¹ ; V. Šmíd ² ; Dostál Š. ²; R. Brůha ² ; P. Dytrych ¹
Authors place of work: I. chirurgická klinika 1. LF UK a VFN v Praze ¹; IV. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze ²
Published in the journal: Gastroent Hepatol 2022; 76(2): 95-100
Category: Original Article
doi: https://doi.org/10.48095/ccgh202295

Summary

Introduction: Liver fibrosis is a consequence of chronic liver disease and often develops covertly over a long period of time. Fibrosis is also a risk factor for extrahepatic diseases, including frailty. The aim of our study was to determine the risk of liver fibrosis in a group of patients with hip trauma. Methods: Patients with surgical treatment of hip trauma were retrospectively evaluated using non-invasive liver fibrosis indices (NAFLD fibrosis score, FIB-4 and APRI score). The control group consisted of patients with diabetes. Results: A total of 72 patients and 72 controls were evaluated. Using the most appropriate index (FIB-4 adjusted for age), 46% of patients had no risk of liver fibrosis, 43% of patients had moderate or indeterminate risk of fibrosis, and 11% of patients were highly likely to have clinically significant fibrosis. Risk stratification did not differ significantly from the controls. The aetiology of liver fibrosis was most likely due to NAFLD or alcohol abuse. Conclusion: Significant liver fibrosis may be present in 1/10 of patients with hip trauma indicated for surgery. Detection of such patients using non-invasive indices is very simple and should be used for screening in common practice.

Keywords:

liver fibrosis – frailty – non-alcoholic fatty liver disease (NAFLD) – hip trauma

Zdroje

1. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis 2007; 27 (4): 413–426. doi: 10.1055/s-2007-991517.

2. Rosselli M, MacNaughtan J, Jalan R et al. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 2013; 62 (9): 1234–1241. doi: 10.1136/gutjnl-2012- 302826.

3. Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. doi: 10.1111/joim.13343.

4. Dulai PS, Singh S, Patel J et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017; 65 (5): 1557–1565. doi: 10.1002/hep.29085.

5. Younossi ZM, Stepanova M, Rafiq N et al. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun 2017; 1 (5): 421–428. doi: 10.1002/hep4.1054.

6. Roulot D, Costes JL, Buyck JF et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60 (7): 977–984. doi: 10.1136/gut.2010.221382.

7. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64 (6): 1388–1402. doi: 10.1016/j.jhep.2015.11.004.

8. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67 (1): 328–357. doi: 10.1002/hep.29367.

9. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34 (3): 274–285. doi: 10.1111/j.1365-2036.2011.04724.x.

10. Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (1): 73–84. doi: 10.1002/hep.28431.

11. Dvorak K, Hainer R, Petrtyl J et al. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159 (3): 442–448. doi: 10.5507/bp.2014.033.

12. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6): 1313–1321. doi: 10.1002/hep.20701.

13. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol 2018; 68 (2): 305–315. doi: 10.1016/j.jhep.2017.11.013.

14. Chalasani N, Abdelmalek MF, Loomba R et al. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int 2019; 39 (5): 924–932. doi: 10.1111/liv.13974.

15. Sumida Y, Yoneda M, Tokushige K et al. FIB-4 first in the diagnostic algorithm of metabolic-dysfunction-associated fatty liver disease in the era of the global metabodemic. Life (Basel) 2021; 11 (2): 143. doi: 10.3390/life11020143.

16. Loosen SH, Roderburg C, Demir M et al. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of osteoporosis and bone fractures. Z Gastroenterol 2021. doi: 10.1055/a-1482-9236.

17. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38 (2): 518–526. doi: 10.1053/jhep.2003.50346.

18. Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46 (1): 32–36. doi: 10.1002/hep.21669.

19. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45 (4): 846–854. doi: 10.1002/hep.21496.

20. Xiao G, Zhu S, Xiao X et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017; 66 (5): 1486–1501. doi: 10.1002/hep.29302.

21. Parikh NS, VanWagner LB, Elkind MSV et al. Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke. J Neurol Sci 2019; 407: 116524. doi: 10.1016/j.jns.2019.116524.

22. Parikh NS, Kumar S, Rosenblatt R et al. Association between liver fibrosis and cognition in a nationally representative sample of older adults. Eur J Neurol 2020; 27 (10): 1895–1903. doi: 10.1111/ene.14384.

23. McPherson S, Hardy T, Dufour JF et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017; 112 (5): 740–751. doi: 10.1038/ajg.2016.453.

24. Zupo R, Castellana F, Donghia R et al. Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study. Geroscience 2021. doi: 10.1007/s11357-021-004 34-x.